There is an increasing concern about underreported and undiscussed side effects of statins, which include the well-known but often dismissed muscle pain and fatigue, as well as increased risk of depression, memory loss, cataracts and neuropathy (nerve degeneration). Statins are also shown to reduce the thyroid-stimulating hormone (TSH), making thyroid tests unreliable if on a statin. Statins are also shown to reduce immunity, increasing the risk of infections, including Methicillin-resistant Staphylococcus aureus (MRSA), as well as reducing the body's ability to repair tissue. New concerns also include evidence that statins increase the risk of developing type II diabetes by nine percent.
Even more concerning is the emerging evidence for significantly increased cancer rates, especially breast cancer, in those taking statins. In one five-year study there was a twelve-fold increase in the incidence of breast cancer in women taking a statin, and other trials are finding that any benefit in reduced cardiovascular mortality may be offset by an increased incidence of cancer. A review study published in the Journal of Cardiology, which included more than 300,000 patient-years, found that the more the low-density lipoprotein (LDL) cholesterol was reduced, the greater the risk of cancer. Those who achieved an LDL level below 100 mg/dl had twice the cancer risk of those who achieved a level of 150 mg/dl. A number of trials have not found any increased incidence of cancer, but these have been severely underrepresented with women and the elderly.
More Answers from Kent Holtorf